Latest News
Viatris Inc.
- FDA Approves RYZUMVI for Presbyopia; Viatris Seeks Commercial Partner
- A new era in pain care: Viatris to absorb Pacira in $1.65bn transaction
- Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B
- Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal
- Viatris to Buy Pacira BioSciences for $1.65 Billion
- Viatris Acquires Pacira BioSciences for $1.65 Billion
- Viatris to make $1.65B Pacira acquisition, adding to momentum in pain
- Harrow Closes Acquisition of Tyrvaya from Viatris
- Viatris’s pipeline strategy: Moving beyond generics to find new growth
- Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
- Viatris sues Novo Nordisk over generic Wegovy patent dispute
Headlines from the last 30 days, linking to the original publishers. See all market news →